Hepatitis C and Human Immunodeficiency Virus Kidney Transplantation: The Mount Sinai Experience.

Clinical transplants Pub Date : 2015-01-01
Vinay Nair, Rafael Khaim, Fadi El-Salem, Rebecca Kent, Susan Lerner, Amnon Berger, Leandra Miko, Brett Rollins, Zeynep Ebcioglu, Veronica Delaney, Vinita Sehgal, Madhav Menon, Scott Ames, Alan Benvenisty, Vikram Wadhera, Antonious Arvelakas, Thomas Schiano, Meena Rana, Shirish Huprikar, Sander Florman, Ron Shapiro
{"title":"Hepatitis C and Human Immunodeficiency Virus Kidney Transplantation: The Mount Sinai Experience.","authors":"Vinay Nair,&nbsp;Rafael Khaim,&nbsp;Fadi El-Salem,&nbsp;Rebecca Kent,&nbsp;Susan Lerner,&nbsp;Amnon Berger,&nbsp;Leandra Miko,&nbsp;Brett Rollins,&nbsp;Zeynep Ebcioglu,&nbsp;Veronica Delaney,&nbsp;Vinita Sehgal,&nbsp;Madhav Menon,&nbsp;Scott Ames,&nbsp;Alan Benvenisty,&nbsp;Vikram Wadhera,&nbsp;Antonious Arvelakas,&nbsp;Thomas Schiano,&nbsp;Meena Rana,&nbsp;Shirish Huprikar,&nbsp;Sander Florman,&nbsp;Ron Shapiro","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Mount Sinai Hospital in New York has a long history in the field of organ transplantation. The first kidney transplant at Mount Sinai was performed in 1967 by the late Dr. Lewis Burrows and the first laparoscopic donor nephrectomy in New York was performed at Mount Sinai in 1996. Over 3000 kidney transplantations have been performed at Mount Sinai. In the early 1990s, the first hepatitis C virus (HCV) positive patient at Mount Sinai underwent a kidney transplant and the first kidney transplant in a patient with human immunodeficiency virus (HIV) in New York was performed at Mount Sinai in 2001. In general, these patients have done well after renal transplantation, with outcomes similar to those seen in non-infected patients. This chapter will describe the evolution of immunosuppressive regimens in HCV positive and HIV positive patients, and will describe the outcomes of kidney transplantation in these patients. Given the favorable outcomes, it is reasonable to continue to offer renal transplantation as a treatment for end stage renal disease patients with HCV and/or HIV.</p>","PeriodicalId":77074,"journal":{"name":"Clinical transplants","volume":"31 ","pages":"69-78"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical transplants","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Mount Sinai Hospital in New York has a long history in the field of organ transplantation. The first kidney transplant at Mount Sinai was performed in 1967 by the late Dr. Lewis Burrows and the first laparoscopic donor nephrectomy in New York was performed at Mount Sinai in 1996. Over 3000 kidney transplantations have been performed at Mount Sinai. In the early 1990s, the first hepatitis C virus (HCV) positive patient at Mount Sinai underwent a kidney transplant and the first kidney transplant in a patient with human immunodeficiency virus (HIV) in New York was performed at Mount Sinai in 2001. In general, these patients have done well after renal transplantation, with outcomes similar to those seen in non-infected patients. This chapter will describe the evolution of immunosuppressive regimens in HCV positive and HIV positive patients, and will describe the outcomes of kidney transplantation in these patients. Given the favorable outcomes, it is reasonable to continue to offer renal transplantation as a treatment for end stage renal disease patients with HCV and/or HIV.

丙型肝炎和人类免疫缺陷病毒肾移植:西奈山的经验。
纽约西奈山医院在器官移植领域有着悠久的历史。1967年,已故的Lewis Burrows医生在西奈山进行了第一例肾移植手术,1996年,纽约第一例腹腔镜供体肾切除术在西奈山进行。西奈山已经进行了3000多例肾脏移植手术。在20世纪90年代初,西奈山医院的第一位丙型肝炎病毒(HCV)阳性患者接受了肾脏移植手术,2001年,纽约首例人类免疫缺陷病毒(HIV)患者在西奈山医院接受了肾脏移植手术。一般来说,这些患者在肾移植后表现良好,其结果与未感染患者相似。本章将描述HCV阳性和HIV阳性患者免疫抑制方案的演变,并将描述这些患者肾移植的结果。鉴于良好的结果,继续提供肾移植作为终末期HCV和/或HIV肾病患者的治疗是合理的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信